{"product_id":"vvos-vrio-analysis","title":"Vivos Therapeutics, Inc. (VVOS): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eDiscover the secret sauce behind Vivos Therapeutics, Inc. (VVOS)'s market position. This VRIO analysis distills whether their core assets are truly Valuable, Rare, Inimitable, and Organized (\u0026amp;O4\u0026amp;), offering a sharp, immediate verdict on their sustainable competitive advantage. Read on to see exactly what sets them apart - or where their vulnerabilities lie.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVivos Therapeutics, Inc. (VVOS) - VRIO Analysis: Proprietary Vivos Method and CARE Devices (Core Technology)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at Vivos Therapeutics, Inc. (VVOS) core technology - the Vivos Method and the CARE devices - through the VRIO lens to see where the real competitive muscle is right now. Honestly, the story is about a pivot toward direct medical integration, which is showing up in the early 2025 numbers.\u003c\/p\u003e\n\n\u003ch3\u003eProprietary Vivos Method and CARE Devices (Core Technology) Assessment\u003c\/h3\u003e\n\u003cp\u003eThe Vivos Method is positioned as a first-of-its-kind, non-surgical, noninvasive, nonpharmaceutical, and cost-effective way to treat mild-to-severe Obstructive Sleep Apnea (OSA) in adults and moderate-to-severe OSA in children ages 6 to 17. This addresses a huge, often underserved market; globally, OSA affects over 1 billion people, but about 90% remain undiagnosed. The global sleep apnea devices market itself is valued at USD 7.11 billion in 2025. The company sold 3,736 oral appliance arches in Q1 2025, up 8% year-over-year in product revenue, showing traction for the devices themselves.\u003c\/p\u003e\n\n\u003cp\u003eThe Vivos Method involves treatment regimens using the proprietary CARE appliance therapy to physically alter the size and shape of the upper airway. This isn’t just another mouthguard; the CARE devices are the only oral appliance to receive FDA 510(k) clearance to treat severe OSA in adults, a significant regulatory hurdle that competitors haven't cleared. This regulatory achievement, coupled with the underlying scientific know-how, creates a high barrier for any competitor trying to replicate the entire protocol.\u003c\/p\u003e\n\n\u003cp\u003eOrganizationally, Vivos Therapeutics is actively executing a strategic shift away from its legacy dental-only distribution to focus on direct medical partnerships and acquisitions. The June 10, 2025, acquisition of The Sleep Center of Nevada (SCN) is the prime example of this, providing direct access to thousands of OSA patients monthly. They are looking to replicate this, exploring alliances or acquisitions of some of the more than 2,500 accredited sleep medicine groups nationwide. This new model is designed to capture both diagnostic and treatment revenue, as seen when SCN added $2.2 million in diagnostic sleep testing revenue in Q3 2025 alone.\u003c\/p\u003e\n\n\u003cp\u003eThe resulting competitive advantage hinges on maintaining this clinical edge and expanding the network. Early data from an alliance showed a 64% treatment case acceptance rate, nearly 2:1 over CPAP, which validates the patient preference for their approach. If Vivos Therapeutics can successfully scale its SCN acquisition model and keep its gross margins in the targeted 50–60% range, this technology could secure a sustained advantage in the non-CPAP segment.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the VRIO components for this core asset:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment for Vivos Method\/CARE Devices\u003c\/td\u003e\n\u003ctd\u003eImplication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes. Addresses massive OSA market (over 1 billion affected globally) with a nonsurgical solution.\u003c\/td\u003e\n\u003ctd\u003eCompetitive Parity at minimum.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes. Only oral appliance with FDA clearance for severe OSA in adults.\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult. Requires significant scientific know-how and successful FDA clearance process.\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eIn Progress. Pivot to medical center acquisitions (like SCN) is underway, showing early revenue impact in Q3 2025.\u003c\/td\u003e\n\u003ctd\u003ePotential for Sustained Advantage.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the current cash burn; operating expenses for Q3 2025 were $8.7 million, leading to a net loss of $5.4 million for the quarter. The success of the VRIO framework depends entirely on the organization scaling this new model faster than cash runs out.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA clearance for severe OSA is a major moat.\u003c\/li\u003e\n\u003cli\u003ePatient preference over CPAP is strong at 2:1.\u003c\/li\u003e\n\u003cli\u003ePivot to medical centers is the key organizational focus.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 revenue grew 76% year-over-year due to the pivot.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVivos Therapeutics, Inc. (VVOS) - VRIO Analysis: Exclusive FDA 510(k) Clearances (Regulatory Moat)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Allows Vivos to legally market their devices for severe adult OSA and pediatric OSA (ages 6-17).\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eDevice(s)\u003c\/th\u003e\n\u003cth\u003eFDA 510(k) Clearance Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSevere Obstructive Sleep Apnea (Adults $\\ge$ 18)\u003c\/td\u003e\n\u003ctd\u003eCARE oral appliances (DNA, mRNA, mmRNA)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNovember 29, 2023\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eModerate to Severe Pediatric OSA and Snoring (Ages 6-17)\u003c\/td\u003e\n\u003ctd\u003eDNA appliance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeptember 18, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: They hold the only FDA 510(k) clearance for severe adult OSA treatment and the first for pediatric moderate-to-severe OSA.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe clearance for severe adult OSA in \u003cstrong\u003eNovember 2023\u003c\/strong\u003e followed the clearance for mild-to-moderate OSA by \u003cstrong\u003e11 months\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Very high; regulatory clearance is a massive barrier requiring years of investment and successful trials.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe time between the initial adult clearance (for mild-to-moderate OSA) and the severe adult clearance was approximately \u003cstrong\u003e11 months\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: The organization is structured to leverage these clearances through the new medical practice model.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePost-severe adult OSA clearance, business metrics showed significant immediate impact:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNew-dentist inquiries jumped an estimated \u003cstrong\u003e600%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSigned dentist enrollment contracts increased \u003cstrong\u003e38%\u003c\/strong\u003e sequentially over Q3 2023.\u003c\/li\u003e\n\u003cli\u003eOrders for VVOS CARE oral medical devices increased \u003cstrong\u003e26%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOne DSO partner saw new-patient inquiries increase by \u003cstrong\u003e1,500%\u003c\/strong\u003e in December.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained; regulatory hurdles create a long-term barrier to entry for direct competitors.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMarket presence and scale built upon clearances:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eApproximately \u003cstrong\u003e58,000\u003c\/strong\u003e patients treated globally as of year-end 2024.\u003c\/li\u003e\n\u003cli\u003eOver \u003cstrong\u003e2,000\u003c\/strong\u003e trained dentists as of year-end 2024.\u003c\/li\u003e\n\u003cli\u003eFY 2024 Revenue: \u003cstrong\u003e$15.0 million\u003c\/strong\u003e, a \u003cstrong\u003e9%\u003c\/strong\u003e increase.\u003c\/li\u003e\n\u003cli\u003eFY 2024 Operating Loss reduction: \u003cstrong\u003e35%\u003c\/strong\u003e to \u003cstrong\u003e$11.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSpecific pediatric study outcomes supporting the pediatric clearance:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eResult\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eReduction in OSA Severity ($\\ge$ 50% reduction)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e77%\u003c\/strong\u003e of participants\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReduction in OSA Severity ($\\ge$ 50% reduction) in Severe OSA patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e93%\u003c\/strong\u003e of participants\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Airway Volume Increase\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e67.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComplete Resolution of OSA\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e17%\u003c\/strong\u003e of patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eADHD Symptoms Resolved\/Rarely Occurred (after $\\sim$7 months)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e61%\u003c\/strong\u003e of children with OSA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eVivos Therapeutics, Inc. (VVOS) - VRIO Analysis: Direct-to-Medical-Practice Acquisition\/Alliance Model (Distribution Strategy)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Captures higher-margin diagnostic and treatment revenue streams, moving away from lower-margin product-only sales.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare, as the pivot away from the dental channel to majority-owned\/managed medical centers is a significant strategic departure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors can attempt acquisitions, but replicating the management structure and integration process is complex.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Organization is clearly aligned, evidenced by the June 10, 2025 SCN acquisition and the July 14, 2025 Michigan management agreement with MISleep Solutions LLC.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the advantage exists now due to first-mover execution, but it erodes as others copy the model.\u003c\/p\u003e\n\u003cp\u003eThe strategic pivot is quantified by the following financial metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eLegacy Model Context (Pre-Pivot\/2024)\u003c\/th\u003e\n\u003cth\u003eDirect-to-Medical-Practice Model (Q3 2025 SCN Contribution)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue (Quarterly)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3.9 million\u003c\/strong\u003e (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$6.8 million\u003c\/strong\u003e (Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Growth (Y\/Y)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e76%\u003c\/strong\u003e Increase (Q3 2025 vs Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Service Revenue Streams (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eVIP Enrollment Revenue: \u003cstrong\u003e$0.9 million\u003c\/strong\u003e (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003eDiagnostic Sleep Testing: \u003cstrong\u003e$2.2 million\u003c\/strong\u003e; Treatment Center Revenue: \u003cstrong\u003e$1.3 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin (GAAP)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e60%\u003c\/strong\u003e (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e58%\u003c\/strong\u003e (Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected SO Team Contribution Margin\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e50% to 60%\u003c\/strong\u003e (Steady State)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eEvidence of capturing higher-margin revenue streams and patient funnel conversion:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSCN historically served over \u003cstrong\u003e200,000\u003c\/strong\u003e OSA patients since 2019, providing a large patient funnel.\u003c\/li\u003e\n\u003cli\u003eIn the first 20 days post-acquisition (June 2025), SCN contributed approximately \u003cstrong\u003e$500,000\u003c\/strong\u003e in diagnostic sleep testing revenue.\u003c\/li\u003e\n\u003cli\u003eJust under \u003cstrong\u003e2\/3\u003c\/strong\u003e of SCN patients presented with a full array of clinical treatment options choose some form of Vivos oral appliance treatment.\u003c\/li\u003e\n\u003cli\u003eThe average dollar amount per case selected by these patients is just over \u003cstrong\u003e$5,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProjected net collections per fully operational Sleep Optimization (SO) team: over \u003cstrong\u003e$500,000\u003c\/strong\u003e monthly, with contribution margins above \u003cstrong\u003e50%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial impact of the transition on the balance sheet and financing:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVivos raised \u003cstrong\u003e$14.2 million\u003c\/strong\u003e in net cash from financing activities for the nine months ended September 30, 2025, to support the pivot and SCN operation.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2025, cash and cash equivalents were \u003cstrong\u003e$3.1 million\u003c\/strong\u003e against total liabilities of \u003cstrong\u003e$23.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe nine-month period ending September 30, 2025, Gross Margin was \u003cstrong\u003e55%\u003c\/strong\u003e, compared to \u003cstrong\u003e61%\u003c\/strong\u003e for the same period in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVivos Therapeutics, Inc. (VVOS) - VRIO Analysis: Validated Patient Preference for Vivos CARE (Market Acceptance)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Shows patients actively choose Vivos over the standard of care (CPAP) when presented with options.\u003c\/p\u003e\n\u003cp\u003eThe selection rate for Vivos' oral appliance therapy over CPAP or inaction in a pilot program was 79% of newly diagnosed adult OSA patients.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; initial alliance data shows patients prefer Vivos treatment nearly 2 to 1 over CPAP.\u003c\/p\u003e\n\u003cp\u003eData from a multi-site pilot involving 76 newly diagnosed adult OSA patients demonstrated the following treatment selection breakdown:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTreatment Option Presented\u003c\/td\u003e\n\u003ctd\u003eCount (out of 76)\u003c\/td\u003e\n\u003ctd\u003ePercentage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChose Vivos Oral Appliance Therapy\u003c\/td\u003e\n\u003ctd\u003e60\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e79%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChose to Investigate CPAP\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeclined All Treatment Options\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe 79% selection rate for Vivos therapy compared to 16% choosing to investigate CPAP suggests a preference ratio significantly greater than 2 to 1 in this initial setting.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; clinical preference is hard to copy directly; it relies on the perceived efficacy of the treatment itself.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVivos CARE appliances received the first-ever FDA 510(k) clearance for an oral device to treat severe OSA on November 2, 2023.\u003c\/li\u003e\n\u003cli\u003eData submitted to the FDA for severe OSA patients showed 80% experienced an improvement of at least 1 classification or at least a 50% improvement in the Apnea Hypopnea Index (AHI), with 97% improving or staying the same.\u003c\/li\u003e\n\u003cli\u003eIn a separate peer-reviewed study, 1 out of 4 Vivos patients experienced a complete resolution of their OSA symptoms (AHI score of less than 5).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The sales\/education process within the new centers is organized to highlight this preference data.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVivos is pivoting to a new marketing and distribution model focused on provider-based acquisitions or alliances.\u003c\/li\u003e\n\u003cli\u003eThe company's network included over 1,950 trained dentists as of mid-2024.\u003c\/li\u003e\n\u003cli\u003eVivos recognized approximately $500,000 of diagnostic sleep testing services revenue over just 20 days from the June 10, 2025, acquisition of The Sleep Center of Nevada (SCN).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; if the 2:1 preference holds true across broader markets, it becomes a powerful marketing asset.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe U.S. CPAP market is valued at $6B and is currently in flux due to recalls impacting over 5 million units from competitors like Philips Respironics.\u003c\/li\u003e\n\u003cli\u003eVivos CARE devices are the only approved oral appliance option for severe OSA patients seeking alternatives to CPAP.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVivos Therapeutics, Inc. (VVOS) - VRIO Analysis: SCN Asset Base and Operational Template (Tangible Resource)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides immediate revenue (Q3 2025 saw \u003cstrong\u003e$2.2 million\u003c\/strong\u003e in sleep testing revenue from SCN) and a blueprint for future expansion. Q3 2025 total revenue was \u003cstrong\u003e$6.8 million\u003c\/strong\u003e, up \u003cstrong\u003e76%\u003c\/strong\u003e year-over-year.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; SCN was the \u003cstrong\u003elargest operator of medical sleep centers in Nevada\u003c\/strong\u003e, providing a ready-made, high-volume platform.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the physical assets are imitable, but the integrated operational playbook developed there is not easily replicated.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is actively using the SCN experience to deploy teams in new markets like Michigan.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the advantage is in the immediate revenue and learning curve, which fades as more centers are integrated.\u003c\/p\u003e\n\u003cp\u003eSCN Operational Metrics as of Q3 2025 Reporting Period (Ended September 30, 2025):\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eSource\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCN Diagnostic Testing Revenue (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 OSA sleep testing revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCN Treatment Center Revenue (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNew revenue stream from SCN operations in Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal SCN Contribution (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSum of diagnostic and treatment center revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCN Locations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeven\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNumber of physical locations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCN Overnight Testing Beds\u003c\/td\u003e\n\u003ctd\u003eNearly \u003cstrong\u003e50\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCapacity for polysomnogram (PSG) testing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCN New Patients Monthly (Historical)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e3,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMonthly patient volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOrganizational Deployment and Capacity Data:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePlanned Sleep Optimization (SO) Teams at SCN by Year-End 2025: \u003cstrong\u003e3.5\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExpansion Markets: Active deployment planning in \u003cstrong\u003eMichigan\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSCN Patient Positivity Rate for OSA: Approximately \u003cstrong\u003e90%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Gross Profit: \u003cstrong\u003e$3.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Gross Margin: \u003cstrong\u003e58%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and Cash Equivalents as of September 30, 2025: \u003cstrong\u003e$3.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVivos Therapeutics, Inc. (VVOS) - VRIO Analysis: Integrated Diagnostic \u0026amp; Treatment Revenue Capture (New Revenue Stream)\n\u003c\/h2\u003e\n\u003cp\u003e\nThe strategic pivot toward direct affiliation and acquisition of medical sleep practices, exemplified by the June 2025 acquisition of The Sleep Center of Nevada (SCN), establishes this integrated revenue capture model.\n\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nCreates two distinct, higher-value revenue streams from a single patient pathway.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eRevenue Stream Component\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Contribution (SCN)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostic Sleep Testing Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTreatment Center Revenue (New Stream)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal SCN Contribution to Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nTotal Vivos Therapeutics Q3 2025 Revenue was \u003cstrong\u003e$6.8 million\u003c\/strong\u003e, representing a \u003cstrong\u003e76%\u003c\/strong\u003e increase year-over-year and a \u003cstrong\u003e78%\u003c\/strong\u003e sequential increase.\n\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nRare; most competitors focus on one or the other, not the integrated capture model Vivos is building.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nThe integrated model captures revenue from both OSA diagnostic procedures and subsequent proprietary treatment device sales\/services.\n\u003c\/li\u003e\n\u003cli\u003e\nAverage dollar amount per case for Vivos oral appliance treatment presented to SCN patients was just over \u003cstrong\u003e$5,000\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nModerate; requires integrating clinical services (testing) with device\/protocol sales, which demands different operational expertise.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nIntegration involved increased Cost of Sales of \u003cstrong\u003e$1.3 million\u003c\/strong\u003e in Q3 2025, reflecting integration costs, staff compensation, and support costs related to SCN.\n\u003c\/li\u003e\n\u003cli\u003e\nOperating Expenses for Q3 2025 rose to \u003cstrong\u003e$8.7 million\u003c\/strong\u003e, a \u003cstrong\u003e74%\u003c\/strong\u003e increase compared to the prior year period, reflecting increased headcount and non-cash expenses from the acquisition.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nThe structure allows for capturing \u003cstrong\u003e$1.3 million\u003c\/strong\u003e in treatment center revenue at SCN in Q3 2025 alone.\n\u003c\/p\u003e\n\u003cp\u003e\nQ3 2025 Gross Profit was \u003cstrong\u003e$3.9 million\u003c\/strong\u003e with a Gross Margin of \u003cstrong\u003e58%\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nSustained; if the model proves financially superior (higher per-case profit potential), it becomes a structural advantage.\n\u003c\/p\u003e\n\u003cp\u003e\nThe new revenue stream is expected to ramp further as additional Vivos sleep optimization teams are formed and deployed.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVivos Therapeutics, Inc. (VVOS) - VRIO Analysis: Management Team's Strategic Pivot Execution (Organizational Skill)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to recognize the limitations of the old model and successfully execute a complex pivot to acquisitions and alliances.\u003c\/p\u003e\n\u003cp\u003eThe strategic pivot away from a reliance on dentists toward direct affiliations with or acquisitions of medical sleep practices is demonstrating top-line success. Revenue for Q3 2025 was reported at \u003cstrong\u003e$6.8 million\u003c\/strong\u003e, marking a \u003cstrong\u003e76%\u003c\/strong\u003e increase year-over-year and a \u003cstrong\u003e78%\u003c\/strong\u003e sequential increase. This pivot was exemplified by the June 10, 2025 acquisition of The Sleep Center of Nevada (SCN). The SCN integration contributed \u003cstrong\u003e$2.2 million\u003c\/strong\u003e in diagnostic sleep testing revenue and \u003cstrong\u003e$1.3 million\u003c\/strong\u003e from new treatment centers in the quarter. Patients choosing Vivos oral appliance treatment have an average dollar amount per case just over \u003cstrong\u003e$5,000\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; many companies fail when attempting such a fundamental shift in sales and distribution channels.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; relies on the specific experience and decision-making of the executive team under Chairman Kirk Huntsman.\u003c\/p\u003e\n\u003cp\u003eChairman and CEO R. Kirk Huntsman has served in his role since September 2016. His prior experience includes founding Dental One, which grew to over \u003cstrong\u003e165 practices\u003c\/strong\u003e before its sale in 2008. The current executive team's tenure profile is:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAverage Management Tenure: \u003cstrong\u003e1.9 years\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eChairman \u0026amp; CEO R. Kirk Huntsman Tenure: Since September 2016\u003c\/li\u003e\n\u003cli\u003eKey Executive: CFO Bradford Amman\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The organization is clearly prioritizing this pivot, even accepting lower gross margins for long-term growth.\u003c\/p\u003e\n\u003cp\u003eThe organizational prioritization is evidenced by the financial trade-offs made during the transition phase. The company accepted a gross margin of \u003cstrong\u003e58%\u003c\/strong\u003e in Q3 2025, which is lower than the \u003cstrong\u003e60%\u003c\/strong\u003e reported in Q3 2024. Operating expenses for Q3 2025 reached \u003cstrong\u003e$8.7 million\u003c\/strong\u003e, a \u003cstrong\u003e74%\u003c\/strong\u003e increase year-over-year, contributing to a net loss of \u003cstrong\u003e($5.4 million)\u003c\/strong\u003e for the quarter.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Amount\u003c\/td\u003e\n\u003ctd\u003eComparative Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e76%\u003c\/strong\u003e year-over-year increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e58%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDown from \u003cstrong\u003e60%\u003c\/strong\u003e in Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCN Revenue Contribution\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSum of \u003cstrong\u003e$2.2M\u003c\/strong\u003e (testing) + \u003cstrong\u003e$1.3M\u003c\/strong\u003e (treatment centers)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e($5.4 million)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReflecting higher costs from business model transition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents (Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDown from $6.3 million at December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; depends on the tenure and continued alignment of key leaders like the CEO and CFO.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVivos Therapeutics, Inc. (VVOS) - VRIO Analysis: Capacity for Rapid Expansion into New Markets (Geographic Potential)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to scale the new model quickly into other major markets beyond the initial success in Nevada and Colorado.\u003c\/p\u003e\n\u003cp\u003eThe strategic pivot to a provider-based model is evidenced by the June \u003cstrong\u003e10, 2025\u003c\/strong\u003e acquisition of The Sleep Center of Nevada (SCN), the largest operator of medical sleep centers in Nevada. Expansion into Colorado includes an immediate expansion of the strategic marketing and distribution alliance with Rebis Health into \u003cstrong\u003e2\u003c\/strong\u003e additional facilities in the greater Denver market. Management is actively exploring alliances or acquisitions of some of the more than \u003cstrong\u003e2,500\u003c\/strong\u003e accredited sleep medicine and testing groups in major United States cities.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; while the intent is common, the proven ability to execute the alliance\/acquisition strategy is not yet widespread.\u003c\/p\u003e\n\u003cp\u003eThe execution involves both acquisitions, such as SCN, and contractual alliances, including the one with Rebis Health and a management agreement entered into with MISleep Solutions LLC on July \u003cstrong\u003e14, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is an organizational capability tied to deal sourcing, financing, and rapid provider onboarding.\u003c\/p\u003e\n\u003cp\u003eThe credentialing process for new providers with third-party insurance payers typically takes anywhere from \u003cstrong\u003e2 to 6 months\u003c\/strong\u003e. Management expects to have sufficient providers fully licensed and credentialed in the first part of \u003cstrong\u003e2026\u003c\/strong\u003e. The SCN acquisition required key investments in people and infrastructure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Management is actively exploring similar arrangements in other major markets, showing readiness to deploy capital.\u003c\/p\u003e\n\u003cp\u003eFinancial activities supporting expansion include raising approximately \u003cstrong\u003e$17.9 million\u003c\/strong\u003e through four separate equity transactions during \u003cstrong\u003e2024\u003c\/strong\u003e. For the 9 months ended September 30, 2025, the company secured \u003cstrong\u003e$14.2 million\u003c\/strong\u003e in net cash from financing activities. The company reported revenue of \u003cstrong\u003e$6.8 million\u003c\/strong\u003e for the three months ended September 30, 2025, a \u003cstrong\u003e76%\u003c\/strong\u003e increase year-over-year, showcasing early impact from the new model.\u003c\/p\u003e\n\u003cp\u003eThe capacity for rapid expansion is demonstrated through initial operational successes in the new model:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eContext\/Location\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlliance Case Acceptance Rate (Vivos vs CPAP)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e64%\u003c\/strong\u003e (nearly \u003cstrong\u003e2:1\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eInitial months of Rebis Health Alliance in Colorado\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePilot Adult Patient Choice for Vivos Therapy\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e79%\u003c\/strong\u003e (\u003cstrong\u003e60\u003c\/strong\u003e out of \u003cstrong\u003e76\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003e7-month, multi-site pilot\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Per Case Revenue\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e$4,700\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eColorado Alliance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin (Pre-Profit Split)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e70%\u003c\/strong\u003e range\u003c\/td\u003e\n\u003ctd\u003eColorado Alliance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCN Acquisition Date\u003c\/td\u003e\n\u003ctd\u003eJune \u003cstrong\u003e10, 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eNevada Market Entry\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this advantage is realized only through successful, rapid execution in the next \u003cstrong\u003e12-18 months\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe new model is expected to generate up to \u003cstrong\u003efour times\u003c\/strong\u003e greater potential profit per case for Vivos compared to the prior distribution model. The company believes it has the necessary tools to implement growth plans and achieve cash flow positive operations in the foreseeable future.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA clearance to treat mild to severe OSA in adults and moderate to severe OSA in children ages \u003cstrong\u003e6 – 17\u003c\/strong\u003e provides credibility for provider recommendations.\u003c\/li\u003e\n\u003cli\u003eFor the 9 months ended September 30, 2025, gross profit increased to \u003cstrong\u003e$7.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePatient appointments at SCN locations were booked out for weeks, with less than \u003cstrong\u003e40%\u003c\/strong\u003e of patients currently being served as of June 30, 2025, indicating immediate demand exceeding initial capacity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVivos Therapeutics, Inc. (VVOS) - VRIO Analysis: Recent Financing Capability (Financial Resource)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eProvided the necessary capital to fund the SCN acquisition and initial operating deficits during the transition.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eModerate; securing \u003cstrong\u003e$14.2 million\u003c\/strong\u003e in net cash from financing in 2025 shows access to capital markets when needed.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eLow; capital access is dependent on market sentiment and the company's current balance sheet (\u003cstrong\u003e$3.1 million\u003c\/strong\u003e cash as of Sept 30, 2025).\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eThe finance function successfully executed complex equity and debt financings to support the strategic pivot.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eTemporary; this resource is consumed by current operations and requires continuous replenishment to sustain growth.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash from Financing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockholders' Equity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Capital Raised\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 for SCN acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eFinancing secured in 2025 included both debt and equity.\u003c\/li\u003e\n\u003cli\u003eThe equity financing in 2025 came from an affiliate of existing significant investor, Cynica Partners.\u003c\/li\u003e\n\u003cli\u003eThe SCN acquisition was closed in June 2025.\u003c\/li\u003e\n\u003cli\u003eOperating expenses for Q3 2025 were \u003cstrong\u003e$8.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet loss for Q3 2025 was \u003cstrong\u003e($5.4 million)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFor the nine months ended September 30, 2025, operating expenses were \u003cstrong\u003e$21.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516279283861,"sku":"vvos-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/vvos-vrio-analysis.png?v=1740230028","url":"https:\/\/dcf-model.com\/es\/products\/vvos-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}